A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancers. A new study has ...

The WEHI research team paired venetoclax, a current standard-of-care anti-cancer drug for AML, with a STING agonist, an emerging class of immunotherapy drugs. Venetoclax was based on a landmark ...

Some GLP-1s are now FDA approved for chronic weight management, including Wegovy (semaglutide) and Saxenda (liraglutide), ...

The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with ...

"The conclusion of enrollment for Regimen G marks a critical step forward for the HEALEY ALS platform Trial," said Drs. Paganoni and Babu. "We extend our thanks to Denali, academic collaborators, and ...

Every single database showed a lower risk for cognitive impairment or dementia among people whose type 2 diabetes was treated ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal second quarter 2024 ...

Three years ago injecting yourself skinny seemed positively futuristic. Now, everyone from Oprah Winfrey and Elon Musk to ...

Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid ...

Gilead Sciences Inc. is aiming to capitalize on the early August 2022 buyout of privately held U.K. biotech Mirobio Ltd. with ...

The director of preventive cardiology at the University of Michigan, says the medications are a promising option for many ...

Kevin C. Gorman; CEO & Director; Neurocrine Biosciences, Inc. Kyle W. Gano; Chief Business Development & Strategy Officer; Neurocrine Biosciences, Inc. Matthew C. Abernethy; CFO; Neurocrine ...